Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in miceHUMAN VACCINES & IMMUNOTHERAPEUTICSIF3.52024-01-081OAAI
Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis controlNATURE IMMUNOLOGYIF27.62023-04-0326PRE
Quantitative Analysis of the Phase Transition Mechanism Underpinning the Systemic Self-Assembly of a Mechanopharmaceutical DevicePHARMACEUTICSIF5.52021-12-224OAAI
An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of ClofaziminePHARMACEUTICSIF5.52021-12-223OAAI
Targeting Unconventional Host Components for Vaccination-Induced Protection Against TBFRONTIERS IN IMMUNOLOGYIF5.92020-07-244OAAI
S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosisJOURNAL OF CLINICAL INVESTIGATIONIF13.62020-05-11100OA
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of TuberculosisANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-07-0133OAAI
Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivoJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62016-10-2549OAAI
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis ChemotherapyANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52016-05-0129OA
Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of TuberculosisANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52015-06-0197OAAI
Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosisPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12015-01-05117OAAI